

Expression pattern of glucocorticoid receptor α gene and associations with clinicolaboratory features in patients with systemic lupus erythematosus

Maryam Sahebari (MD)¹
 Zahra Rezaieyazdi (MD)¹
 Mandana Khodashahi (MD)¹
 Houshang Rafatpanah (MD)²
 Hassan Mehrad-Majd (PhD)³
 Nayereh Saadati (MD)¹
 Masoumeh Salari (MD)^{1*}

1. Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
 2. Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
 3. Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

* Correspondence:

Masoumeh Salari, Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

E-mail: salarim@mums.ac.ir
 Tel: +98 5138012753

Abstract

Background: Glucocorticoid receptor α (GR α) gene is a transcription factor with clinically significant immune-modulating properties in various autoimmune diseases. However, the expression pattern of the GR α gene and associations with clinical features in patients with systemic lupus erythematosus (SLE) is controversial. This study aimed to assess the correlation between the GR α expression and different clinical and laboratory-related parameters in SLE patients.

Methods: A total of 45 women with newly diagnosed SLE and 31 gender and age-matched healthy controls were enrolled in this cross-sectional study. The real-time quantitative PCR (qRT-PCT) method evaluated the differences in GR α expression in peripheral blood mononuclear cells from cases and controls. The correlation between the GR α gene expression levels, clinicolaboratory features, and potential prognostic application was also analyzed.

Results: Compared to the healthy individuals, the GR α gene expression in newly diagnosed SLE patients who did not receive any treatment was numerically reduced, but this reduction did not achieve statistical significance (P=0.87). No significant correlation was also found with the activity and severity of SLE according to SLEDAI2K (P=0.41). The GR α gene expression showed a negative correlation with CRP (P=0.034) and a positive correlation with lupus anticoagulant (P=0.039) levels in SLE. The receiver operating characteristic (ROC) curve analysis indicated that the GR α expression level might be a predictor biomarker for low CRP and positive lupus anticoagulant in SLE, respectively.

Conclusion: This study proposed that expression of the GR α in newly diagnosed lupus patients has no statistically significant difference with healthy age and sex-matched controls. Besides, its expression does not correlate with lupus disease activity according to SLEDAI2k. However, further studies in this area are required.

Keywords: Systemic lupus erythematosus; GR α gene; CRP; Lupus; Glucocorticoid gene receptor.

Citation:

Sahebari M, RezaieYazdi Z, Khodashahi M, et al. Expression pattern of glucocorticoid receptor α gene and associations with clinicolaboratory features in patients with systemic lupus erythematosus. Caspian J Intern Med 2023; 14(3): 470-478.

Systemic lupus erythematosus (SLE), as one of the most well-known autoimmune diseases in women, is an autoimmune disease with diverse clinical presentation, complex pathogenesis, and multiple etiologies (1,2). Despite considerable efforts for finding the best therapeutic strategy for SLE patients, still, glucocorticoids are the most available and lifesaving option for the treatment of SLE (3). In the majority of the cases, the response rate to glucocorticoids is favorable to ameliorate the symptoms of the disease significantly. However, the risk of glucocorticoids resistance could threaten the life of a particular group of patients (1).

Received: 12 April 2022
 Revised: 30 July 2022
 Accepted: 10 Sep 2022



© The Author(s)

Publisher: Babol University of Medical Sciences

It should be noted that the glucocorticoid-resistance not only could attenuate the therapeutic effects of exogenous glucocorticoids but also induce resistance even to endogenous glucocorticoids (4,5). According to the current therapeutic protocol, higher doses of glucocorticoids are being used in resistant patients, increasing the risk of morbidity due to organ damage, opportunistic infections, osteoporosis, and avascular necrosis (6). Thus far, several mechanisms of resistance to glucocorticoids have been identified; however, alteration in the expression level of glucocorticoid receptors (GRs) might confer resistance phenotype in lupus (7-10). GRs are members of nuclear hormone receptors that, in response to glucocorticoids, translocate from the cytosol into the nucleus. They could orchestrate a wide range of physiological functions by regulating the expression of different downstream genes (7, 11). Two isoforms of GRs have been so far identified, which among them, GR α is the dominant receptor form. A few hypotheses proposed that the expression of GR α in SLE patients and thereby accelerate the progression of the disease. Although the genetic abnormalities in the GR α gene encoding, such as polymorphisms. Glucocorticoids play an essential role in inhibiting inflammatory cascades and cytokines. Therefore, the use of glucocorticoids is the first line of treatment in many autoimmune diseases. During lupus, it is expected that the expression of the receptor gene, followed by the expression of glucocorticoids at the cellular level, will decrease and cause the onset of inflammation. Whether this hypothesis can be associated with clinical and laboratory symptoms is discussed in this article. (12-14), overexpression of p-glycoprotein (p-GPro) (15,16), the elevation of macrophage migration inhibitory factor (MIF) (17), and overexpression of TLR9 (18) are all the other postulated mechanisms that could indirectly reduce the expression of the GR α in lupus. In a study conducted on 60 SLE patients, it became evident that those patients with a severe type of the disease had higher expression of p-Gpro than their healthy counterparts (19), suggesting that the expression of this protein could be associated with the aggressive type of the disease. In another study, it has also been reported that the elevated expression of MIF could accelerate the progression of SLE in the patients through MAPK-dependent suppression of GR α (20). Despite the importance of understanding the mechanisms that lead to the downregulation of the gene encoding this receptor, taking the veil off the roles GR α gene might play in the pathogenesis of the disease could also be beneficial for the management and treatment of SLE. Thus far, the majority of the studies suggest that the

downregulation of the GR α gene occurs. Given this and based on the importance of the GR α gene expression in the pathogenesis of the disease, the present study was designed to explore the relationship between the GR α expression level, risk of SLE, disease severity, and related clinical and laboratory features.

Methods

Patients: According to the estimated sample size based on the GR gene expression levels in patients with SLE and corresponding healthy controls in a previously published study (13), With $\alpha=0/05$, $\beta=0/20$ (80% power), at least 43 people are needed in each group. Forty-five women aged more than 18 years with newly diagnosed systemic lupus erythematosus (SLE) referred to Rheumatic Diseases Research Center (RDRC) were enrolled in the present cross-sectional study. SLE was diagnosed according to the SLICC-2012 criteria (21). All patients did not receive any medication before the study. Those previously treated with corticosteroids, or those with other autoimmune diseases, overlap syndromes, and endocrine diseases with elevated or decreased expression of endogen glucocorticoids, were excluded from the study. SLEDAI-2k is a scoring system through which SLE patients could be categorized into mild (score < 4), moderate (score =4-10), and severe (score > 10) groups (22). Moreover, 45 healthy women without any familial history of SLE were selected to be the control group. The median age of the patient (34.8 ± 9.9 years) and the control group (37.8 ± 4.1 years) was quite the same ($P = 0.074$). Blood samples were collected from all included subjects. The sample of 14 healthy individuals was discarded from the study due to insufficient volume or clotting. The number of individuals in the control group was reduced to 31. All participants signed an informed consent form, and the Ethics Committee of Mashhad University of Medical Sciences approved the study protocol (ID number: IR.MUMS.MEDICAL.1397.470).

Peripheral Blood Mononuclear cell (PBMCs) isolation: About 3 mL of fresh blood samples in the tube containing EDTA, as an anticoagulant, were mixed with 3 mL of PBS and ficole. After centrifuging at 2500 rpm for 20 minutes, the buffy coat layer was isolated and transferred into a PBS tube. The mixture was centrifuged for 10 min at 2500 rpm, the supernatant was discarded, and the pellets containing peripheral blood mononuclear cells (PBMCs) were dissolved into 0.5 mL of PBS for further evaluation.

RNA extraction and the qRT-PCR analysis: PBMCs were exposed to an RNA extraction reagent named TriPure

(Roche, Germany) to extract RNA from all samples. The quantity of the extracted RNAs was measured at the wavelength of 260 nm using NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Moreover, agarose gel electrophoresis was done to test the quality of RNAs. For each patient, 2µg of extracted RNAs were used to synthesize the complementary DNA (cDNA) using a cDNA synthesis kit (revertAid First Strand cDNA Synthesis Kit (Takara BIO)). The synthesized cDNA, along with the specific primers; (GR α , 5'-TGCCGCTATCGAAAATGTCTT-3' (forward), 5'-GGGTAGGGGTGAGTTGTGGT-3' (reverse); β 2-microglobulin (β 2M), 5'-CTTGTCTTTCAGCAAGGACTGG-3' (forward) and 5'-CCACTTA ACTATCTTGGGCTGG-3' (reverse)), were then subjected to SYBR green-based real-time quantitative polymerase chain reaction (qRT-PCR) (light cycler, Roche, Germany). The condition for thermal cycling was as follows; initial activation step of 30 s at 95 °C, 40 cycles of a denaturation step (15 s at 95 °C), and a combined annealing/extension step (60 s at 60 °C). An endogenous control was performed by using β 2 microglobulin (β 2M), the result of GR α expression was normalized to β 2M expression, and the relative quantity of the gene of interest was normalized to the relative quantity of β 2M and was reported as relative mRNA expression.

Statistical analysis: All statistical analyses were performed by IBM SPSS Statistics 25, and a p-value < 0.05 was considered statistically significant. The chi-square and t-tests were applied to assess the possible association between GR α expression levels and risk of SLE and related phenotypes. Mann-Whitney test or Spearman correlation analysis was also used to evaluate any association between GR α expression levels and clinical parameters. Moreover, to determine the sensitivity, specificity, and likelihood ratios of GR α gene expression and the levels of CRP and lupus anticoagulant test, receiver operating characteristic analysis (ROC) was performed.

Results

The expression of GR α gene in patients with systemic lupus erythematosus (SLE). This study chose two groups of SLE patients with the median age of 34.8 \pm 9.9 years and the control group with the median age of 37.8 \pm 4.1 years old (P = 0.07). Demographic, clinical, and biochemical data of 45 SLE patients and 31 healthy controls are presented in tables 1 and 2). Comparing the physical features of both groups, we found that the BMI of the SLE group was

significantly lower (P = 0.001). Apart from the physical features, the results of the qRT-PCR analysis revealed that although the expression of GR α was lower in the PBMCs isolated from SLE patients as compared with the control group, this reduction was not statistically significant (P = 0.870) (figure 1).

The correlation between GR α gene expression and the activity and severity of the disease. To evaluate the association of the GR α gene expression with some clinical features in patients, disease activity was divided into mild (score < 4), moderate (score = 4-10), and severe (score > 10) based on the SLEDAI-2k scoring system. Twenty-three (51%) patients had the moderate type of the disease, and 22 (49%) patients suffered from the severe type of the disease. Compared with the patients with moderate SLE, those who had a severe type of the disease had non-significant lower expression levels of the GR α gene. Mann-Whitney result also indicated the lack of association between GR α gene expression levels and the activity and severity of the disease (P = 0.414) (figure. 2).

The correlation between GR α gene expression and the clinical laboratory features of SLE patients. As presented in the Table 1, GR α gene expression had no significant correlation with mouth ulcer (P = 0.08), butterfly rash (P = 0.45), hair loss (P = 0.8), fever (P = 0.7), headache (P = 0.76), CVA (P = 0.13), vasculitis (P = 0.87), arthritis (P = 0.96), myositis (P = 0.85), and serositis (P = 0.70). Correlation analysis between GR α gene expression levels and various laboratory parameters of the patients such as proteinuria, hematuria, sterile pyuria, glomerular filtration rate (GFR), ANA, anti-dsDNA, anti-Sm, anti-cardiolipin, anti- β 2 glycoprotein, lupus anticoagulant, ESR, leukopenia, lymphopenia, thrombocytopenia, anemia, CRP, C3 and C4 deficiency was also performed. As shown in table 2 GR α gene expression was inversely correlated with CRP (P = 0.032). Moreover, a significant positive correlation was found regarding lupus anticoagulant (P = 0.039) (table 2). The overall sensitivity and specificity of GR α gene expression for CRP and lupus anticoagulant values in SLE patients. The ROC curve analyses were performed to evaluate if GR α gene expression can cause molecular discrimination of SLE patients with and without altered CRP and lupus anticoagulant levels. As presented in fig. 3, the optimal cut-off values of GR α expression levels to differentiate SLE patients with altered CRP levels from normal ones was 290.58, with a sensitivity of 70%, specificity 68%, and area under the curve = 0.70. Moreover, ROC analyses revealed a cut-off value of 160.75 with 82% and 64% sensitivity and specificity, respectively, for the

GR α expression levels and area under the curve = 0.71 for the positive lupus anticoagulant test (figure 4).

Table 1. The correlation between GR α gene expression and the laboratory clinical feature of SLE patients

Clinicopathologic symptoms	Median GR α expression levels	P-value
Oral ulcer		
Positive (n = 16)	289.4	0.08
Negative (n = 29)	285.8	
Butterfly rash		
Positive (n = 21)	269.1	0.45
Negative (n = 24)	405.3	
Hair loss (alopecia)		
Positive (n = 17)	275.4	0.88
Negative (n = 28)	321	
Fever (>37.5 °C axillary)		
Positive (n = 7)	275.4	0.7
Negative (n = 38)	290.5	
Headache		
Positive (n = 2)	266.4	0.76
Negative (n = 43)	295.3	
CVA		
Positive (n = 1)	1373.7417	0.13
Negative (n = 44)	280.6	
Vasculitis		
Positive (n = 5)	263.6	0.87
Negative (n = 40)	290.5	
Arthritis		
Positive (n = 32)	290.5	0.96
Negative (n = 13)	275.4	
Myositis		
Positive (n = 6)	316.3	0.85
Negative (n = 39)	285.8	
Serositis		
Positive (n = 9)	263.6	0.79
Negative (n = 36)	290.5	

CVA: cerebrovascular accident

Table 2. Correlation between GR α gene expression and the laboratory parameters of SLE patients

Laboratory parameters	Median GR α expression levels	P-value
ANA		
Positive (n = 41)	275.4	0.577
Negative (n = 2)	372.7	
Anti-dsDNA		
Positive (n = 39)	275.4	0.503
Negative (n = 6)	515.5	
Anti-Sm		
Positive (n = 9)	507.3	0.104
Negative (n = 36)	265.5	

Laboratory parameters	Median GR α expression levels	P-value
Anti-cardiolipin antibody		
Positive (n = 14)	332.3	0.590
Negative (n = 31)	285.8	
Anti-β2 glycoprotein antibody		
Positive (n = 13)	269.1	0.689
Negative (n = 32)	290.5	
Lupus anticoagulant		
Positive (n = 11)	150.7	0.039
Negative (n = 34)	356.8	
Leukopenia (WBC<4000x10⁹/L)		
Positive (n = 18)	272.2	0.694
Negative (n = 27)	356.2	
Lymphopenia (1500 x10⁹/L)		
Positive (n = 18)	373.3	0.266
Negative (n = 27)	267.4	
Thrombocytopenia (<100,000x10⁹/L)		
Positive (n = 10)	280.6	0.925
Negative (n = 35)	295.3	
Anemia (hemoglobin<12 g/L)		
Positive (n = 24)	330.4	0.179
Negative (n = 21)	267.4	
Decreased GFR (<60 CC/min)		
Positive (n = 8)	289.4	0.694
Negative (n = 37)	285.8	
Elevated ESR*		
Positive (n = 33)	269.1	0.315
Negative (n = 12)	401.3	
CRP		
Positive (n = 20)	405.3	0.032
Negative (n = 25)	180.4	
C4 deficiency		
Positive (n = 23)	356.2	0.414
Negative (n = 22)	250.6	
C3 deficiency		
Positive (n = 23)	357.3	0.093
Negative (n = 22)	250.6	
Hematuria		
Positive (n = 14)	272.2	0.825
Negative (n = 31)	295.3	
Proteinuria**		
Positive (n = 13)	269.1	0.582
Negative (n = 32)	325.7	
Pyuria		
Positive (n = 9)	272.2	0.825
Negative (n = 36)	295.3	

*Calculated according to the age of patients

** more than 500mg/24h

GFR=glomerular filtration rate, ESR=erythrocyte sedimentation rate, CRP=c-reactive protein, C4= complement component 4, C3= complement component 3




Figure 1. GR- α mRNA expression levels in PBMCs from 45 SLE patients and 31 healthy controls




Figure 2. GR α mRNA expression in SLE patients subgroups based on the SLEDAI-2K scores




Figure 3. The ROC curve for determining the GR- α expression cutoff value for identifying SLE patients with elevated CRP levels. AUC=0.70; 95% CI: 0.53–0.85, P=0.034




Figure 4. ROC curve for determining the GR- α expression cutoff value for identifying SLE patients with elevated LAC levels. AUC=0.71; 95% CI: 0.53–0.88, P=0.039

Discussion

The For a long time, systemic lupus erythematosus (SLE) pathogenesis was under a magnifying glass, and several mechanisms have been proposed to describe the

formation of the disease. Thus far, no medication is effective as glucocorticoids for ameliorating the disease symptoms; however, some patients showed resistance phenotype based on the response rate (23). It has also been

reported that the aberrancy in the GR α gene expression and its downregulation may attenuate the glucocorticoid effectiveness and induce glucocorticoid resistance in SLE (16). Given these, in the present study, we aimed to evaluate whether the expression of gene encoding GR α , the dominant form of GRs, could determine the outcome of the newly diagnosed SLE patients. Interestingly, our results showed that comparing with the aged-matched healthy individuals, the expression levels of the GR α gene were reduced in SLE patients before treatment, suggesting that it could reduce the expression of the receptor. We also found that patients with severe disease had lower expression of the GR α gene than those with a more significant activity of the disease. However, the expression of this receptor gene did not have an association with the activity of the disease. In agreement with our results, Du et al. have also reported that the downregulation in the GR α gene expression is associated with the induction of resistance against glucocorticoids (24). In another study conducted on 15 SLE patients, it became evident that the expression of the GR α gene has a lower level as compared to the healthy counterparts due to the hypermethylation of GR α promoter (25). Li et al. have indicated that the expression of the GR α gene was significantly downregulated in SLE patients as compared to the control group. However, unlike our results, they also succeeded in finding a correlation between the expression of this receptor and the SLE Disease Activity Index scores (13). It should be noted that perhaps the difference in the sample size and the bodyweight could be the restrictions that explain why we failed to find any correlation between the disease severity, the clinical and the laboratory features of SLE patients, and the GR α gene expression levels.

Among the long list of parameters, we found a significant correlation between the downregulation of the GR α gene and the values of CRP and lupus anticoagulant in SLE patients. As a standard inflammatory marker in SLE patients, so far, numerous studies have evaluated the correlation between the expression levels of the GR α gene and the values of CRP. However, in many cases, there are conflicting results. Manenschijn et al. have indicated that ER22/23EK polymorphism in the GR α gene, associated with glucocorticoid resistance induction, correlates with the reduced CRP levels (26). In contrast, Kuningas et al. have reported that the SLE patients who had such polymorphisms in gene encoding GR α manifested the higher values of CRP (27). In the present study, we reported that those SLE patients with the reduced levels of GR α gene had higher values of CRP which can be a sign of inflammation.

Moreover, we reported that GR α gene expression levels had 70% sensitivity and 68% specificity to predict CRP values in the patients. We also reported for the first time that GR α gene expression levels could have a positive correlation with lupus anticoagulant levels with the sensitivity of 82%. It is well-established that lupus anticoagulant is a significant risk factor for SLE patients' arterial and venous thrombotic complications (28). The results of previous studies have introduced the triangle between lupus anticoagulant, C3, and C4 deficiency as an indicator of thrombosis and obstetric complications in the patients (29-31). In a study conducted by Rasuli-Saravani et al., it has also been reported that there is human leukocyte antigen (HLA) gene complex that could control the lupus anti-coagulant levels in Iranian patients with SLE (32).

Given this association, it is reasonable to assume that HLA polymorphism could be a reason that we found a positive correlation between downregulation in the GR α gene and the expression of lupus anti-coagulant in sera of patients. This study was not without limitations, due to targeting newly diagnosed patients which is the strong point of the study who did not receive treatment, we could not increase the sample size. Taken together, the results of the present study declared that although it was not significant, GR α gene expression downregulation in SLE patients as compared to the healthy counterparts, we found a negative correlation between the expression of the GR α gene and CRP value and a positive correlation between that gene expression and lupus anticoagulant positivity. Moreover, GR α gene expression did not correlate with lupus disease activity and severity according to SLEDAI2k. However, further studies in this area are required.

Acknowledgments

The authors would like to thank the Clinical Research Development Center, Ghaem Hospital, Mashhad University of Medical Sciences for this manuscript.

Funding: The study was financially supported by Mashhad University Research Council (approval code: 961829). The data presented in this article has derived from the Fellowship thesis of Dr. Masoumeh Salari for achieving specialty in the rheumatology subspecialty (Thesis number: T5400).

Conflict of Interests: The authors declare no conflict of interest.

Ethics Committee approval: All patients and volunteers were provided with written informed consent, and the

protocol was reviewed and approved by the Institutional Review Board of Mashhad University of Medical Sciences (ID number: IR.MUMS.MEDICAL.1397.470)

Consent to participate: All patients signed a consent form before attending the study.

Authors' contribution: All authors contributed equally to write the manuscript. This manuscript has been read and approved by all authors.

References

1. Lam NC, Ghetu MV, Bieniek ML. Systemic lupus erythematosus: primary care approach to diagnosis and management. *Am Fam Physician* 2016; 94: 284-94.
2. Rastin M, Mahmoudi M, Hatef M, et al. T lymphocyte apoptosis in systemic lupus erythematosus patients. *Iran J Basic Med Sci* 2013; 16: 936-41.
3. Mosca M, Tani C, Carli L, Bombardieri S. Glucocorticoids in systemic lupus erythematosus. *Clinical and Experimental Rheumatology-Incl Supplements*. 2011; 29: S126-9.
4. Seguro LP, Rosario C, Shoenfeld Y. Long-term complications of past glucocorticoid use. *Autoimmun Rev* 2013; 12: 629-32.
5. Arnaud L, Zahr N, Costedoat-Chalumeau N, Amoura Z. The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. *Autoimmun Rev* 2011; 10: 674-8.
6. Stojan G, Petri M. The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years? *Curr Treatm Opt Rheumatol* 2017; 3: 164-72.
7. Bazsó A, Szappanos Á, Patócs A, et al. The importance of glucocorticoid receptors in systemic lupus erythematosis. A systematic review. *Autoimmun Rev* 2015; 14: 349-51.
8. Piotrowski P, Burzynski M, Lianeri M, et al. Glucocorticoid receptor beta splice variant expression in patients with high and low activity of systemic lupus erythematosus. *Folia Histochem Cytobiol* 2007; 45: 339-42.
9. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative β isoform: a mechanism for the generation of glucocorticoid resistance. *Proc Natl Acad Sci* 2001; 98: 6865-70.
10. Morishima Y, Kanelakis KC, Murphy PJ, et al. The hsp90 cochaperone p23 is the limiting component of the multiprotein hsp90/hsp70-based chaperone system in vivo where it acts to stabilize the client protein· hsp90 complex. *J Biol Chem* 2003; 278: 48754-63.
11. Van Everdingen AA, Huisman AM, Wenting MJ, et al. Down-regulation of glucocorticoid receptors in early-diagnosed rheumatoid arthritis. *Clin Exp Rheumatol* 2002; 20: 463-8.
12. Quax RA, Peeters RP, Feelders RA. Selective glucocorticoid receptor modulators: future of glucocorticoid immunosuppressive therapy? *Endocrinology* 2011; 152: 2927-9.
13. Li X, Zhang FS, Zhang JH, Wang JY. Negative relationship between expression of glucocorticoid receptor α and disease activity: glucocorticoid treatment of patients with systemic lupus erythematosus. *J Rheumatol* 2010; 37: 316-21.
14. Zou YF, Xu JH, Wang F, et al. Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study. *Autoimmunity* 2013; 46: 531-6.
15. Perez-Guerrero EE, Gamez-Nava JI, Muñoz-Valle JF, et al. Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus. *Clin Exp Med* 2018; 18: 109-17.
16. Gao H WQ, Yu X, Liu J, et al. Molecular mechanisms of glucocorticoid resistance in systemic lupus erythematosus: A review. *Life Sci* 2018; 209: 383-7.
17. Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. *Nature* 1995; 377: 68-71.
18. Yuan Y, Yang M, Wang K, et al. Excessive activation of the TLR9/TGF- β 1/PDGF-B pathway in the peripheral blood of patients with systemic lupus erythematosus. *Arthritis Res Ther* 2017; 19: 70.
19. Zhang B, Shi Y, Lei TC. Detection of active P-glycoprotein in systemic lupus erythematosus patients with poor disease control. *Exp Ther Med* 2012; 4: 705-10.
20. Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. *Eur J Immunol* 2005; 35: 3405-13.
21. Inês L, Silva C, Galindo M, et al. Classification of systemic lupus erythematosus: Systemic Lupus International Collaborating Clinics versus American

- College of Rheumatology criteria. A comparative study of 2,055 patients from a real-life, international systemic lupus erythematosus cohort. *Arthritis Care Res* 2015; 67: 1180-5.
22. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997; 40: 1725.
23. Gurevitz S, Snyder J, Wessel E, Frey J, Williamson B. Systemic lupus erythematosus: a review of the disease and treatment options. *Consult Pharm* 2013; 28: 110-21.
24. Du J, Li M, Zhang D, et al. Flow cytometry analysis of glucocorticoid receptor expression and binding in steroid-sensitive and steroid-resistant patients with systemic lupus erythematosus. *Arthritis Res Ther* 2009; 11: R108.
25. Chen H, Fan J, Shou Q, Zhang L, Ma H, Fan Y. Hypermethylation of glucocorticoid receptor gene promoter results in glucocorticoid receptor gene low expression in peripheral blood mononuclear cells of patients with systemic lupus erythematosus. *Rheumatol Int* 2015; 35: 1335-42.
26. Manenschijn L, Van Den Akker EL, Lamberts SW, Van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms: an overview. *Ann N Y Acad Sci* 2009; 1179: 179-98.
27. Schouwers SM, Delanghe JR, Devreese KM. Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results? *Thromb Res* 2010; 125: 102-4.
28. Horbach DA, Oort EV, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. *Throm Haemost* 1996; 76: 916-24.
29. Petri MA, Conklin J, O'Malley T, Dervieux T. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. *Lupus Sci Med* 2019; 6: e000318.
30. Svenungsson E, Gustafsson JT, Grosso G, et al. Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus. *Rheumatology* 2020; 59: 3264-74.
31. Mankee A, Petri M, Magder LS. Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss. *Lupus Sci Med* 2015; 2: e000095.
32. Rasouli-Saravani A, Tahamoli-Roudsari A, Basiri Z, et al. Relevance of autoantibody profile with HLA-DRB1 and-DQB1 alleles in a group of Iranian systemic lupus erythematosus patients. *Immunol Lett* 2021; 237: 11-6.